Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 199

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 199
---
 shares of Common Stock being offered for resale by this prospectus, which consist of:

| ● | an aggregate of 10,169,406 shares of Common Stock issued as merger consideration shares in connection with the Liminatus Merger, which shares were issued at a deemed value of $10.00 per share pursuant to the terms of the Business Combination Agreement; |

| ● | an aggregate of 6,900,000 shares of Common Stock issued to the Sponsor upon conversion of founder shares prior to the IPO, which shares were purchased by the Sponsor at a price per share of $0.004; |

| ● | an aggregate of 1,500,000 shares of Common Stock issued to the PIPE Investor pursuant to the PIPE Equity Subscription Agreement; |

| ● | an aggregate of 835,555 shares of Common Stock issuable upon the exercise of 835,555 Private Warrants, which were originally issued concurrently with the IPO in a private placement to Cantor at a price of $1.50 per Warrant, with each warrant exercisable for one share of Common Stock at $11.50 per share; |

| ● | up to 700,000 shares of Common Stock issued to Cantor in settlement of $7.0 million in deferred underwriting fees; and |

| ● | up to 350,000 shares of Common Stock issued to Alta pursuant to a settlement and release agreement. |

In addition, this prospectus relates to the issuance of up to 6,900,000 shares of Common Stock that are issuable upon the exercise of the Public Warrants, at an exercise price per share of $11.50, contained in the units sold at a price of $10.00 per unit in the IPO. The Common Stock being registered for resale in connection with this offering will constitute a considerable percentage of our outstanding shares of Common Stock. We are registering for resale on behalf of the Selling Securityholders an aggregate of 19,619,406 shares of Common Stock, not including the shares underlying the Warrants. The shares of Common Stock being registered for resale in this prospectus (excluding the shares underlying the Warrants) constitutes approximately 72.5% of our total outstanding shares. The Selling Securityholders, including Chris Kim, Liminatus’ Founder and our Chief Executive Officer, the beneficial owner of approximately 23.1% of our outstanding shares of Common Stock, will be able to sell all of their shares for so long as the registration statement of which this prospectus forms a part is available